These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 3573331)

  • 1. [A simple analytic method of the activation mechanism of factor IX using Western blotting].
    Sakai T; Ohkubo Y; Tanaka I; Yamamoto K; Yoshioka A; Fukui H
    Rinsho Ketsueki; 1987 Jan; 28(1):47-52. PubMed ID: 3573331
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
    Bertina RM; van der Linden IK
    Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple method for analyzing factor IX activation in the patients with hemophilia B variants.
    Yoshioka A; Sakai T; Yamamoto K; Ohkubo Y; Fukui H
    Thromb Haemost; 1987 Aug; 58(2):705-8. PubMed ID: 3499681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
    Bertina RM; Van Der Linden IK
    J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
    Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI
    Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
    de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
    Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
    Osterud B; Kasper CK; Prodanos C
    Thromb Res; 1979; 15(1-2):235-43. PubMed ID: 483278
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
    Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
    Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX.
    Chung KS; Goldsmith JC; Roberts HR
    Bibl Haematol; 1977; 44():68-74. PubMed ID: 617785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor IX of the blood coagulation system: a review.
    Taran LD
    Biochemistry (Mosc); 1997 Jul; 62(7):685-93. PubMed ID: 9331959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of canine factor IX.
    Sugahara Y; Catalfamo J; Brooks M; Hitomi E; Bajaj SP; Kurachi K
    Thromb Haemost; 1996 Mar; 75(3):450-5. PubMed ID: 8701406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe haemophilia B due to a 6 kb factor IX gene deletion including exon 4: non-homologous recombination associated with a shortened transcript from whole blood.
    Hsu TC; Nakaya SM; Thompson AR
    Thromb Haemost; 2007 Feb; 97(2):176-80. PubMed ID: 17264943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor IX gene therapy for hemophilia.
    Fewell JG
    Methods Mol Biol; 2008; 423():375-82. PubMed ID: 18370215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative two-stage assay for factor IX (Christmas factor) using plasma from dogs with Christmas disease.
    Aronson DL; Dodds WJ; Mustafa AJ
    Thromb Diath Haemorrh; 1972 Jul; 27(3):529-34. PubMed ID: 4662614
    [No Abstract]   [Full Text] [Related]  

  • 16. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.
    Herzog RW; Arruda VR; Fisher TH; Read MS; Nichols TC; High KA
    Thromb Haemost; 2000 Aug; 84(2):352-4. PubMed ID: 10959714
    [No Abstract]   [Full Text] [Related]  

  • 18. The structure and function of factors VIII and IX.
    Austen DE
    Clin Haematol; 1979 Feb; 8(1):31-52. PubMed ID: 367665
    [No Abstract]   [Full Text] [Related]  

  • 19. Structure and function of factor IX: defects in haemophilia B.
    McGraw RA; Davis LM; Lundblad RL; Stafford DW; Roberts HR
    Clin Haematol; 1985 Jun; 14(2):359-83. PubMed ID: 3899439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preparation of factor IX deficient plasma by immunoadsorption using monoclonal antibody (3A6) to factor IX and its application].
    Nishimura T; Ohkubo Y; Nishino M; Sakai T; Sawai J; Tanaka I; Takamiya O; Yoshioka A
    Rinsho Byori; 1986 Apr; 34(4):469-74. PubMed ID: 3528584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.